Gladstone Institutional Advisory’s Cardiff Oncology CRDF Stock Holding History

Gladstone Institutional Advisory’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.1K	Hold	13,000	–	–	﹤0.01%	827
2025 Q4	$36.5K	Hold	13,000	–	–	﹤0.01%	785
2025 Q3	$26.8K	Hold	13,000	–	–	﹤0.01%	782
2025 Q2	$41K	Hold	13,000	–	–	﹤0.01%	749
2025 Q1	$40.8K	Hold	13,000	–	–	﹤0.01%	710
2024 Q4	$56.4K	Sell	13,000 -2,000	-13%	-$6.25K	﹤0.01%	692
2024 Q3	$40K	Hold	15,000	–	–	﹤0.01%	677
2024 Q2	$33.3K	Hold	15,000	–	–	﹤0.01%	654
2024 Q1	$80.1K	Hold	15,000	–	–	﹤0.01%	627
2023 Q4	$22.2K	Hold	15,000	–	–	﹤0.01%	663
2023 Q3	$20.9K	Buy	15,000 +1,000	+7%	+$1.69K	﹤0.01%	616
2023 Q2	$20.6K	Hold	14,000	–	–	﹤0.01%	625
2023 Q1	$23.1K	Hold	14,000	–	–	﹤0.01%	648
2022 Q4	$19.6K	Hold	14,000	–	–	﹤0.01%	638
2022 Q3	$22K	Buy	+14,000	New	+$33.7K	﹤0.01%	625

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Gladstone Institutional Advisory's CRDF Position: Q1 2026 in Review

Gladstone Institutional Advisory held its Cardiff Oncology (CRDF) position steady in Q1 2026 at 13,000 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #827.

Gladstone Institutional Advisory first reported a position in CRDF in Q3 2022 and has held it in 15 quarters since. The position peaked at $80.1K in Q1 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

Gladstone Institutional Advisory held 13,000 shares of Cardiff Oncology worth $21.1K as of Q1 2026.
Gladstone Institutional Advisory left its Cardiff Oncology share count unchanged in Q1 2026.
Cardiff Oncology made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q1 2026, its #827 holding.
Gladstone Institutional Advisory first reported a position in Cardiff Oncology in Q3 2022 and has held it in 15 quarters since.
Gladstone Institutional Advisory's Cardiff Oncology position peaked at $80.1K in Q1 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2026, filed 14 May 2026.